Identification of novel markers for neuroblastoma immunoclustering using machine learning

被引:0
作者
Zhang, Longguo [1 ,2 ]
Li, Huixin [1 ,2 ]
Sun, Fangyan [1 ,2 ]
Wu, Qiuping [1 ,2 ]
Jin, Leigang [1 ,2 ]
Xu, Aimin [1 ,2 ]
Chen, Jiarui [3 ,4 ]
Yang, Ranyao [1 ,2 ,5 ]
机构
[1] Univ Hong Kong, State Key Lab Pharmaceut Biotechnol, Hong Kong, Peoples R China
[2] Univ Hong Kong, Dept Med, Hong Kong, Peoples R China
[3] Sun Yat Sen Univ, Sch Publ Hlth, Guangdong Prov Key Lab Food Nutr & Hlth, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Sch Publ Hlth, Dept Nutr, Guangzhou, Peoples R China
[5] Shandong First Med Univ, Jining Peoples Hosp 1, Dept Clin Pharm, Jining, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
基金
中国国家自然科学基金;
关键词
biomarker; tumor microenvironment; immunoclustering; machine learning; neuroblastoma; CANCER; GENE; PROGRESSION; RECEPTORS; SELECTION; BLOCKADE; CELLS;
D O I
10.3389/fimmu.2024.1446273
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Due to the unique heterogeneity of neuroblastoma, its treatment and prognosis are closely related to the biological behavior of the tumor. However, the effect of the tumor immune microenvironment on neuroblastoma needs to be investigated, and there is a lack of biomarkers to reflect the condition of the tumor immune microenvironment.Methods The GEO Database was used to download transcriptome data (both training dataset and test dataset) on neuroblastoma. Immunity scores were calculated for each sample using ssGSEA, and hierarchical clustering was used to categorize the samples into high and low immunity groups. Subsequently, the differences in clinicopathological characteristics and treatment between the different groups were examined. Three machine learning algorithms (LASSO, SVM-RFE, and Random Forest) were used to screen biomarkers and synthesize their function in neuroblastoma.Results In the training set, there were 362 samples in the immunity_L group and 136 samples in the immunity_H group, with differences in age, MYCN status, etc. Additionally, the tumor microenvironment can also affect the therapeutic response of neuroblastoma. Six characteristic genes (BATF, CXCR3, GIMAP5, GPR18, ISG20, and IGHM) were identified by machine learning, and these genes are associated with multiple immune-related pathways and immune cells in neuroblastoma.Conclusions BATF, CXCR3, GIMAP5, GPR18, ISG20, and IGHM may serve as biomarkers that reflect the conditions of the immune microenvironment of neuroblastoma and hold promise in guiding neuroblastoma treatment.
引用
收藏
页数:15
相关论文
共 63 条
  • [1] Data-driven identification of prognostic tumor subpopulations using spatially mapped t-SNE of mass spectrometry imaging data
    Abdelmoula, Walid M.
    Balluff, Benjamin
    Englert, Sonja
    Dijkstra, Jouke
    Reinders, Marcel J. T.
    Walch, Axel
    McDonnell, Liam A.
    Lelieveldt, Boudewijn P. F.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (43) : 12244 - 12249
  • [2] G Protein-Coupled receptors and heterotrimeric G proteins as cancer drivers
    Arang, Nadia
    Gutkind, J. Silvio
    [J]. FEBS LETTERS, 2020, 594 (24) : 4201 - 4232
  • [3] Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma
    Asgharzadeh, Shahab
    Salo, Jill A.
    Ji, Lingyun
    Oberthuer, Andre
    Fischer, Matthias
    Berthold, Frank
    Hadjidaniel, Michael
    Liu, Cathy Wei-Yao
    Metelitsa, Leonid S.
    Pique-Regi, Roger
    Wakamatsu, Peter
    Villablanca, Judith G.
    Kreissman, Susan G.
    Matthay, Katherine K.
    Shimada, Hiroyuki
    London, Wendy B.
    Sposto, Richard
    Seeger, Robert C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) : 3525 - 3532
  • [4] Significance of MYCN Amplification in International Neuroblastoma Staging System Stage 1 and 2 Neuroblastoma: A Report From the International Neuroblastoma Risk Group Database
    Bagatell, Rochelle
    Beck-Popovic, Maja
    London, Wendy B.
    Zhang, Yang
    Pearson, Andrew D. J.
    Matthay, Katherine K.
    Monclair, Tom
    Ambros, Peter F.
    Cohn, Susan L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (03) : 365 - 370
  • [5] Children's Oncology Group's 2023 blueprint for research: Neuroblastoma
    Bagatell, Rochelle G.
    DuBois, Steven G.
    Naranjo, Arlene
    Belle, Jen C.
    Goldsmith, Kelly C. R.
    Park, Julie R. S.
    Irwin, Meredith S.
    COG Neuroblastoma Comm
    [J]. PEDIATRIC BLOOD & CANCER, 2023, 70
  • [6] Tumor microenvironment complexity and therapeutic implications at a glance
    Baghba, Roghayyeh
    Roshangar, Leila
    Jahanban-Esfahlan, Rana
    Seidi, Khaled
    Ebrahimi-Kalan, Abbas
    Jaymand, Mehdi
    Kolahian, Saeed
    Javaheri, Tahereh
    Zare, Peyman
    [J]. CELL COMMUNICATION AND SIGNALING, 2020, 18 (01)
  • [7] Dysfunction of antigen processing and presentation by dendritic cells in cancer
    Bandola-Simon, Joanna
    Roche, Paul A.
    [J]. MOLECULAR IMMUNOLOGY, 2019, 113 : 31 - 37
  • [8] Management of Neuroblastoma: ICMR Consensus Document
    Bansal, Deepak
    Totadri, Sidharth
    Chinnaswamy, Girish
    Agarwala, Sandeep
    Vora, Tushar
    Arora, Brijesh
    Prasad, Maya
    Kapoor, Gauri
    Radhakrishnan, Venkatraman
    Laskar, Siddharth
    Kaur, Tanvir
    Rath, G. K.
    Bakhshi, Sameer
    [J]. INDIAN JOURNAL OF PEDIATRICS, 2017, 84 (06) : 446 - 455
  • [9] Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
    Boussiotis, Vassiliki A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18) : 1767 - 1778
  • [10] REVISIONS OF THE INTERNATIONAL CRITERIA FOR NEUROBLASTOMA DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT
    BRODEUR, GM
    PRITCHARD, J
    BERTHOLD, F
    CARLSEN, NLT
    CASTEL, V
    CASTLEBERRY, RP
    DEBERNARDI, B
    EVANS, AE
    FAVROT, M
    HEDBORG, F
    KANEKO, M
    KEMSHEAD, J
    LAMPERT, F
    LEE, REJ
    LOOK, AT
    PEARSON, ADJ
    PHILIP, T
    ROALD, B
    SAWADA, T
    SEEGER, RC
    TSUCHIDA, Y
    VOUTE, PA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) : 1466 - 1477